Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Clinical trial NCT04584255 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04584255
Sponsor: Dana-Farber Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Stage I Breast Cancer Stage II Breast Cancer Stage III Breast Cancer Breast Cancer HER2-negative Breast Cancer Germline BRCA1 Gene Mutation Germline BRCA2 Gene Mutation Deleterious PALB2 Gene Mutation

Start date: 2020-12-18
Primary completion: 2025-07-01
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.